{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:57:49Z","timestamp":1784347069176,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiol med"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1007\/s11547-022-01479-4","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T01:03:41Z","timestamp":1648515821000},"page":"560-570","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Postoperative moderately hypofractionated radiotherapy in prostate cancer: a mono-institutional propensity-score-matching analysis between adjuvant and early-salvage radiotherapy"],"prefix":"10.1007","volume":"127","author":[{"given":"Luca","family":"Nicosia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Mazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0390-9511","authenticated-orcid":false,"given":"Francesco","family":"Cuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Figlia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Giaj-Levra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ricchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Rigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruggiero","family":"Ruggeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cavalleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Alongi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,26]]},"reference":[{"key":"1479_CR1","unstructured":"European Commission. Estimates of cancer incidence and mortality in 2020, for all countries. Eur Com (2020). Online access on 2 April 2021. https:\/\/ecis.jrc.ec.europa.eu\/explorer.php?$0-1$1-All$2-All$4-1,2$3-0$6-0,85$5-2004,2010$7-2$CRatesByRegistry$X0_10-ASR_EU_NEW"},{"issue":"3","key":"1479_CR2","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","volume":"181","author":"IM Thompson","year":"2009","unstructured":"Thompson IM, Tangen CM, Paradelo J et al (2009) Adjuvant radiotherapy for pathologic T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 181(3):956\u2013962. https:\/\/doi.org\/10.1016\/j.juro.2008.11.032","journal-title":"J Urol"},{"issue":"9858","key":"1479_CR3","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","volume":"380","author":"M Bolla","year":"2012","unstructured":"Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, Verbaeys A, Bosset JF, van Velthoven R, Colombel M, van de Beek C, Verhagen P, van den Bergh A, Sternberg C, Gasser T, van Tienhoven G, Scalliet P, Haustermans K, Collette L (2012) Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380(9858):2018\u201327 (Epub 2012 Oct 19)","journal-title":"Lancet"},{"issue":"2","key":"1479_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","volume":"66","author":"T Wiegel","year":"2014","unstructured":"Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, Golz R, St\u00f6rkel S, Willich N, Semjonow A, St\u00f6ckle M, R\u00fcbe C, Rebmann U, K\u00e4lble T, Feldmann HJ, Wirth M, Hofmann R, Engenhart-Cabillic R, Hinke A, Hinkelbein W, Miller K (2014) Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96\u201302\/AUO AP 09\/95 trial. Eur Urol 66(2):243\u2013250. https:\/\/doi.org\/10.1016\/j.eururo.2014.03.011 (Epub 2014 Mar 21)","journal-title":"Eur Urol"},{"key":"1479_CR5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.critrevonc.2015.09.005","volume":"97","author":"S Arcangeli","year":"2016","unstructured":"Arcangeli S, Ramella S, De Bari B, Franco P, Alongi F, D\u2019Angelillo RM (2016) A cast of shadow on adjuvant radiotherapy for prostate cancer: A critical review based on a methodological perspective. Crit Rev Oncol Hematol 97:322\u20137. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.09.005 (Epub 2015 Oct 9)","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"1479_CR6","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.clon.2014.02.012","volume":"26","author":"P Sundaresan","year":"2014","unstructured":"Sundaresan P, Turner S, Kneebone A, Pearse M, Fraser-Browne C, Woo HH (2014) Do screening trial recruitment logs accurately reflect the eligibility criteria of a given clinical trial? Early lessons from the RAVES 0803 trial. Clin Oncol (R Coll Radiol) 26(6):348\u2013352. https:\/\/doi.org\/10.1016\/j.clon.2014.02.012 (Epub 2014 Mar 27)","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1479_CR7","first-page":"716","volume":"10","author":"JY Bruce","year":"2012","unstructured":"Bruce JY, Lang JM, McNeel DG, Liu G (2012) Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol 10:716\u2013722","journal-title":"Clin Adv Hematol Oncol"},{"issue":"10","key":"1479_CR8","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, Williams SG, Brown C, Delprado W, Haworth A, Joseph DJ, Martin JM, Matthews JHL, Millar JL, Sidhom M, Spry N, Tang CI, Turner S, Wiltshire KL, Woo HH, Davis ID, Lim TS, Pearse M (2020) Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 0803\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol 21(10):1331\u20131340. https:\/\/doi.org\/10.1016\/S1470-2045(20)30456-3","journal-title":"Lancet Oncol"},{"issue":"10260","key":"1479_CR9","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","volume":"396","author":"CC Parker","year":"2020","unstructured":"Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, Cross W, Logue J, Parulekar W, Payne H, Persad R, Pickering H, Saad F, Anderson J, Bahl A, Bottomley D, Brasso K, Chahal R, Cooke PW, Eddy B, Gibbs S, Goh C, Gujral S, Heath C, Henderson A, Jaganathan R, Jakobsen H, James ND, Kanaga Sundaram S, Lees K, Lester J, Lindberg H, Money-Kyrle J, Morris S, O\u2019Sullivan J, Ostler P, Owen L, Patel P, Pope A, Popert R, Raman R, R\u00f8der MA, Sayers I, Simms M, Wilson J, Zarkar A, Parmar MKB, Sydes MR (2020) Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet 396(10260):1413\u20131421. https:\/\/doi.org\/10.1016\/S0140-6736(20)31553-1","journal-title":"Lancet"},{"issue":"10","key":"1479_CR10","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, Chabaud S, Latorzeff I, Magn\u00e9 N, Benyoucef A, Supiot S, Pasquier D, Abdiche MS, Gilliot O, Graff-Cailleaud P, Silva M, Bergerot P, Baumann P, Belkacemi Y, Azria D, Brihoum M, Souli\u00e9 M, Richaud P (2020) Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol 21(10):1341\u20131352. https:\/\/doi.org\/10.1016\/S1470-2045(20)30454-X","journal-title":"Lancet Oncol"},{"issue":"9","key":"1479_CR11","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1007\/s11547-018-0890-7","volume":"123","author":"B De Bari","year":"2018","unstructured":"De Bari B, Mazzola R, Aiello D, Fersino S, Gregucci F, Alongi P, Nicodemo M, Cavalleri S, Salgarello M, Alongi F (2018) Could 68-Ga PSMA PET\/CT become a new tool in the decision-making strategy of prostate cancer patients with biochemical recurrence of PSA after radical prostatectomy? A preliminary, monocentric series. Radiol Med 123(9):719\u2013725. https:\/\/doi.org\/10.1007\/s11547-018-0890-7","journal-title":"Radiol Med"},{"issue":"Suppl 5","key":"1479_CR12","doi-asserted-by":"publisher","first-page":"S538","DOI":"10.21037\/tau.2019.12.34","volume":"8","author":"R Mazzola","year":"2019","unstructured":"Mazzola R, Cuccia F, Figlia V, Giaj-Levra N, Nicosia L, Ricchetti F, Rigo M, Pasinetti N, Salgarello M, Alongi F (2019) New metabolic tracers for detectable PSA levels in the post-prostatectomy setting: is the era of melting glaciers upcoming? Transl Androl Urol 8(Suppl 5):S538\u2013S541. https:\/\/doi.org\/10.21037\/tau.2019.12.34","journal-title":"Transl Androl Urol"},{"key":"1479_CR13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.euros.2020.10.001","volume":"22","author":"S Mahase","year":"2020","unstructured":"Mahase S, Nagar H (2020) Hypofractionated postoperative radiotherapy for prostate cancer: Is the field ready yet? Eur Urol Open Sci 22:9\u201316. https:\/\/doi.org\/10.1016\/j.euros.2020.10.001","journal-title":"Eur Urol Open Sci"},{"key":"1479_CR14","unstructured":"European Association of Urology (EAU) prostate cancer guidelines. Online access on 2 April 2021. https:\/\/uroweb.org\/wp-content\/uploads\/EAU-EANM-ESTRO_ESUR_ISUP_SIOG-Guidelines-on-Prostate-Cancer.pdf"},{"key":"1479_CR15","unstructured":"National Comprehensive Cancer Network (NCCN) prostate cancer guidelines. Online access on 2 April 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf"},{"issue":"4","key":"1479_CR16","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.eururo.2009.05.041","volume":"56","author":"P Ost","year":"2009","unstructured":"Ost P, Fonteyne V, Villeirs G, Lumen N, Oosterlinck W, De Meerleer G (2009) Adjuvant high-dose intensity-modulated radiotherapy after radical prostatectomy forprostate cancer: clinical results in 104 patients. Eur Urol 56(4):669\u2013675. https:\/\/doi.org\/10.1016\/j.eururo.2009.05.041","journal-title":"Eur Urol"},{"key":"1479_CR17","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1200\/JCO.2015.63.3529","volume":"33","author":"P Ghadjar","year":"2015","unstructured":"Ghadjar P, Hayoz S, Bernhard J et al (2015) Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09\/10. J Clin Oncol 33:4158\u20134166","journal-title":"J Clin Oncol"},{"key":"1479_CR18","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.ijrobp.2008.12.059","volume":"75","author":"C Cozzarini","year":"2009","unstructured":"Cozzarini C, Montorsi F, Fiorino C et al (2009) Need for high radiation dose (>70 Gy) in early postoperative irradiation after radical prostatectomy: a single-institution analysis of 334 high-risk, node-negative patients. Int J Radiat Oncol Biol Phys 75:966\u2013974","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1479_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3109\/0284186X.2013.837584","volume":"53","author":"T Zilli","year":"2014","unstructured":"Zilli T, Jorcano S, Peguret N, Caparrotti F, Hidalgo A, Khan HG, Vees H, Weber DC, Miralbell R (2014) Dose-adapted salvage radiotherapy after radical prostatectomy based on an erMRI target definition model: toxicity analysis. Acta Oncol 53(1):96\u2013102. https:\/\/doi.org\/10.3109\/0284186X.2013.837584 (Epub 2013 Sep 13)","journal-title":"Acta Oncol"},{"issue":"6","key":"1479_CR20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3389\/fonc.2016.00048","volume":"1","author":"M Beck","year":"2016","unstructured":"Beck M, Barelkowski T, Kaul D, Wecker S, Thieme AH, Zwahlen DR, Wust P, Aebersold DM, Budach V, Ghadjar P (2016) Role of dose intensification for salvage radiation therapy after radical prostatectomy. Front Oncol 1(6):48. https:\/\/doi.org\/10.3389\/fonc.2016.00048","journal-title":"Front Oncol"},{"issue":"8","key":"1479_CR21","doi-asserted-by":"publisher","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","volume":"51","author":"A Dasu","year":"2012","unstructured":"Dasu A, Toma-Dasu I (2012) Prostate alpha\/beta revisited \u2013 an analysis of clinical results from 14 168 patients. Acta Oncol 51(8):963\u2013974. https:\/\/doi.org\/10.3109\/0284186X.2012.719635 (Epub 2012 Sep 12)","journal-title":"Acta Oncol"},{"issue":"6","key":"1479_CR22","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.prro.2018.08.002","volume":"8","author":"SC Morgan","year":"2018","unstructured":"Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H (2018) Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO, and AUA evidence-based guideline. Pract Radiat Oncol 8(6):354\u2013360. https:\/\/doi.org\/10.1016\/j.prro.2018.08.002","journal-title":"Pract Radiat Oncol"},{"issue":"10","key":"1479_CR23","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1007\/s00432-019-02983-3","volume":"145","author":"L Nicosia","year":"2019","unstructured":"Nicosia L, Mazzola R, Rigo M, Figlia V, Giaj-Levra N, Napoli G, Ricchetti F, Corradini S, Ruggieri R, Alongi F (2019) Moderate versus extreme hypofractionated radiotherapy: a toxicity comparative analysis in low- and favorable intermediate-risk prostate cancer patients. J Cancer Res Clin Oncol 145(10):2547\u20132554. https:\/\/doi.org\/10.1007\/s00432-019-02983-3","journal-title":"J Cancer Res Clin Oncol"},{"key":"1479_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ctrv.2017.11.004","volume":"62","author":"C Picardi","year":"2018","unstructured":"Picardi C, Perret I, Miralbell R, Zilli T (2018) Hypofractionated radiotherapy for prostate cancer in the postoperative setting: What is the evidence so far? Cancer Treat Rev 62:91\u201396. https:\/\/doi.org\/10.1016\/j.ctrv.2017.11.004 (Epub 2017 Nov 14)","journal-title":"Cancer Treat Rev"},{"key":"1479_CR25","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03274687"},{"issue":"1","key":"1479_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13014-019-1325-x","volume":"14","author":"SA Koerber","year":"2019","unstructured":"Koerber SA, Katayama S, Sander A, Jaekel C, Haefner MF, Debus J, Herfarth K (2019) Prostate bed irradiation with alternative radio-oncological approaches (PAROS) - a prospective, multicenter and randomized phase III trial. Radiat Oncol 14(1):122. https:\/\/doi.org\/10.1186\/s13014-019-1325-x","journal-title":"Radiat Oncol"},{"issue":"24","key":"1479_CR27","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJM199912093412401","volume":"341","author":"EM Messing","year":"1999","unstructured":"Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D (1999) Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341(24):1781\u20131788. https:\/\/doi.org\/10.1056\/NEJM199912093412401","journal-title":"N Engl J Med"},{"issue":"5","key":"1479_CR28","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/s0360-3016(02)03052-3","volume":"54","author":"WU Shipley","year":"2002","unstructured":"Shipley WU, Lu JD, Pilepich MV, Heydon K, Roach M, Wolkov HB, Sause WT, Rubin P, Lawton CA, Machtay M (2002) Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86\u201310. Int J Radiat Oncol Biol Phys 54(5):1302\u20131310. https:\/\/doi.org\/10.1016\/s0360-3016(02)03052-3","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1479_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.radonc.2007.07.017","volume":"84","author":"P Poortmans","year":"2007","unstructured":"Poortmans P, Bossi A, Vandeputte K, Bosset M, Miralbell R, Maingon P, Boehmer D, Budiharto T, Symon Z, van den Bergh AC, Scrase C, Van Poppel H, Bolla M (2007) EORTC radiation oncology group guidelines for target volume definition in post-operative radiotherapy for prostate cancer, on behalf of the EORTC radiation oncology group. Radiother Oncol 84(2):121\u20137. https:\/\/doi.org\/10.1016\/j.radonc.2007.07.017","journal-title":"Radiother Oncol"},{"key":"1479_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-021-01435-8","author":"G Francolini","year":"2021","unstructured":"Francolini G, Stocchi G, Detti B, Di Cataldo V, Bruni A, Triggiani L, Guerini AE, Mazzola R, Cuccia F, Mariotti M, Salvestrini V, Garlatti P, Borghesi S, Ingrosso G, Bellavita R, Aristei C, Desideri I, Livi L (2021) Dose-escalated pelvic radiotherapy for prostate cancer in definitive or postoperative setting. Radiol Med. https:\/\/doi.org\/10.1007\/s11547-021-01435-8","journal-title":"Radiol Med"},{"issue":"12","key":"1479_CR31","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1007\/s12094-021-02665-y","volume":"23","author":"G Francolini","year":"2021","unstructured":"Francolini G, Timon G, Matrone F, Marvaso G, Nicosia L, Ognibene L, Vinciguerra A, Trodella LE, Franzese C, Borghetti P, Jereczek-Fossa BA, Arcangeli S (2021) Postoperative radiotherapy after upfront radical prostatectomy: debated issues at a turning point-a survey exploring management trends on behalf of AIRO (Italian Association of Radiotherapy and Clinical Oncology). Clin Transl Oncol 23(12):2568\u20132578. https:\/\/doi.org\/10.1007\/s12094-021-02665-y","journal-title":"Clin Transl Oncol"},{"issue":"10","key":"1479_CR32","first-page":"4537","volume":"33","author":"F Alongi","year":"2013","unstructured":"Alongi F, Cozzi L, Fogliata A et al (2013) Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer. Anticancer Res 33(10):4537\u20134543","journal-title":"Anticancer Res"},{"issue":"6","key":"1479_CR33","first-page":"2785","volume":"33","author":"M Massaccesi","year":"2013","unstructured":"Massaccesi M, Cilla S, Deodato F et al (2013) Hypofractionated intensitymodulated radiotherapy with simultaneous integrated boost after radical prostatectomy: preliminary results of a phase II trial. Anticancer Res 33(6):2785\u20132789","journal-title":"Anticancer Res"},{"issue":"3","key":"1479_CR34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ijrobp.2015.11.025","volume":"94","author":"SL Lewis","year":"2016","unstructured":"Lewis SL, Patel P, Song H et al (2016) Image guided Hypofractionated postprostatectomy intensity modulated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 94(3):605\u2013611","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"1479_CR35","first-page":"5821","volume":"37","author":"G Macchia","year":"2017","unstructured":"Macchia G, Siepe G, Capocaccia I et al (2017) Hypofractionated postoperative IMRT in prostate carcinoma: a Phase I\/II Study. Anticancer Res 37(10):5821\u20135828","journal-title":"Anticancer Res"},{"issue":"10","key":"1479_CR36","doi-asserted-by":"publisher","first-page":"5053","DOI":"10.2147\/CMAR.S182016","volume":"29","author":"F Cuccia","year":"2018","unstructured":"Cuccia F, Mortellaro G, Serretta V, Valenti V, Tripoli A, Gueci M, Luca N, Lo Casto A, Ferrera G (2018) Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes. Cancer Manag Res 29(10):5053\u20135060. https:\/\/doi.org\/10.2147\/CMAR.S182016","journal-title":"Cancer Manag Res"},{"issue":"3","key":"1479_CR37","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bju.14924","volume":"125","author":"G Francolini","year":"2020","unstructured":"Francolini G, Jereczek-Fossa BA, Di Cataldo V, Simontacchi G, Marvaso G, Zerella MA, Gentile P, Bianciardi F, Allegretta S, Detti B, Masi L, Lo Russo M, Livi L (2020) Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series. BJU Int 125(3):417\u2013425. https:\/\/doi.org\/10.1111\/bju.14924","journal-title":"BJU Int"},{"issue":"4","key":"1479_CR38","doi-asserted-by":"publisher","first-page":"e667","DOI":"10.1016\/j.clgc.2017.01.025","volume":"15","author":"S Fersino","year":"2017","unstructured":"Fersino S, Tebano U, Mazzola R et al (2017) Moderate hypofractionated postprostatectomy volumetric modulated arc therapy with daily image guidance (VMAT-IGRT): a mono-institutional report on feasibility and acute toxicity. Clin Genitourin Cancer 15(4):e667\u2013e673","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"1479_CR39","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1002\/cncr.25824","volume":"117","author":"TJ Kruser","year":"2011","unstructured":"Kruser TJ, Jarrard DF, Graf AK, Hedican SP, Paolone DR, Wegenke JD, Liu G, Geye HM, Ritter MA (2011) Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer 117(12):2629\u20132636. https:\/\/doi.org\/10.1002\/cncr.25824","journal-title":"Cancer"},{"issue":"2","key":"1479_CR40","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.ijrobp.2007.06.042","volume":"70","author":"GW Wong","year":"2008","unstructured":"Wong GW, Palazzi-Churas KL, Jarrard DF, Paolone DR, Graf AK, Hedican SP, Wegenke JD, Ritter MA (2008) Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. Int J Radiat Oncol Biol Phys 70(2):449\u2013455. https:\/\/doi.org\/10.1016\/j.ijrobp.2007.06.042","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1479_CR41","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.ijrobp.2014.07.015","volume":"90","author":"S Katayama","year":"2014","unstructured":"Katayama S, Striecker T, Kessel K et al (2014) Hypofractionated IMRT of the prostate bed after radical prostatectomy: acute toxicity in the PRIAMOS-1 trial. Int J Radiat Oncol Biol Phys 90(4):926\u2013933","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1479_CR42","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.juro.2013.05.032","volume":"190","author":"IM Thompson","year":"2013","unstructured":"Thompson IM, Valicenti RK, Albertsen P et al (2013) Adjuvant and salvage radiotherapy after prostatectomy: AUA\/ASTRO Guideline. J Urol 190(2):441\u2013449","journal-title":"J Urol"},{"issue":"2","key":"1479_CR43","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.ijrobp.2020.01.008","volume":"107","author":"S Chin","year":"2020","unstructured":"Chin S, Fatimilehin A, Walshaw R, Argarwal A, Mistry H, Elliott T, Logue J, Wylie J, Choudhury A (2020) Ten-year outcomes of moderately hypofractionated salvage postprostatectomy radiation therapy and external validation of a contemporary multivariable nomogram for biochemical failure. Int J Radiat Oncol Biol Phys 107(2):288\u2013296. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.01.008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1479_CR44","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ijrobp.2009.08.023","volume":"78","author":"SK Nath","year":"2010","unstructured":"Nath SK, Sandhu AP, Rose BS et al (2010) Toxicity analysis of postoperative image-guided intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 78(2):435\u2013441","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1479_CR45","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1748-717X-7-158","volume":"7","author":"C Azelie","year":"2012","unstructured":"Azelie C, Gauthier M, Mirjolet C et al (2012) Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups. Radiat Oncol 7:158","journal-title":"Radiat Oncol"},{"issue":"10","key":"1479_CR46","first-page":"750","volume":"31","author":"WJ Wu","year":"2017","unstructured":"Wu WJ, Potters L (2017) Counterpoint: early salvage vs adjuvant radiotherapy for high-risk prostate cancer: the data for adjuvant radiotherapy remain strong. Oncology 31(10):750","journal-title":"Oncology"},{"issue":"3","key":"1479_CR47","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s12094-018-1931-3","volume":"21","author":"F Casas","year":"2019","unstructured":"Casas F, Valduvieco I, Oses G, Izquierdo L, Archila I, Costa M, Cortes KS, Barreto T, Ferrer F (2019) Postoperative adjuvant and very early salvage radiotherapy after prostatectomy in high-risk prostate cancer patients can improve specific and overall survival. Clin Transl Oncol 21(3):355\u2013362. https:\/\/doi.org\/10.1007\/s12094-018-1931-3","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"1479_CR48","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.urolonc.2010.10.005","volume":"31","author":"E Ippolito","year":"2013","unstructured":"Ippolito E, Cellini N, Diges\u00f9 C, Cilla S, Mantini G, Balducci M, Di Lallo A, Deodato F, Macchia G, Massaccesi M, Mattiucci GC, Tagliaferri L, Piermattei A, Cuscun\u00e0 D, Morganti AG (2013) Postoperative intensity-modulated radiotherapy with simultaneous integrated boost in prostate cancer: a dose-escalation trial. Urol Oncol 31(1):87\u201392. https:\/\/doi.org\/10.1016\/j.urolonc.2010.10.005","journal-title":"Urol Oncol"},{"issue":"6","key":"1479_CR49","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.eururo.2014.06.012","volume":"66","author":"C Cozzarini","year":"2014","unstructured":"Cozzarini C, Fiorino C, Deantoni C, Briganti A, Fodor A, La Macchia M, Noris Chiorda B, Rancoita PM, Suardi N, Zerbetto F, Calandrino R, Montorsi F, Di Muzio N (2014) Higher-than-expected severe (Grade 3\u20134) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients. Eur Urol 66(6):1024\u20131030. https:\/\/doi.org\/10.1016\/j.eururo.2014.06.012","journal-title":"Eur Urol"},{"issue":"11","key":"1479_CR50","doi-asserted-by":"publisher","first-page":"e496","DOI":"10.1097\/RLU.0000000000000841","volume":"40","author":"F Alongi","year":"2015","unstructured":"Alongi F, Fersino S, Giaj Levra N, Mazzola R, Ricchetti F, Fiorentino A, Ruggieri R, Malfatti V, Cavalleri S, Salgarello M (2015) Impact of 18F-choline PET\/CT in the decision-making strategy of treatment volumes in definitive prostate cancer volumetric modulated radiation therapy. Clin Nucl Med 40(11):e496-500. https:\/\/doi.org\/10.1097\/RLU.0000000000000841","journal-title":"Clin Nucl Med"},{"issue":"20","key":"1479_CR51","doi-asserted-by":"publisher","first-page":"30191","DOI":"10.1016\/j.clgc.2020.08.002","volume":"S1558\u20137673","author":"R Mazzola","year":"2020","unstructured":"Mazzola R, Francolini G, Triggiani L, Napoli G, Cuccia F, Nicosia L, Livi L, Magrini SM, Salgarello M, Alongi F (2020) Metastasis-directed therapy (SBRT) guided by PET-CT 18F-CHOLINE versus PET-CT 68Ga-PSMA in castration-sensitive oligorecurrent prostate cancer: a comparative analysis of effectiveness. Clin Genitourin Cancer S1558\u20137673(20):30191\u201330199. https:\/\/doi.org\/10.1016\/j.clgc.2020.08.002","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"1479_CR52","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s00066-019-01523-9","volume":"196","author":"L Nicosia","year":"2020","unstructured":"Nicosia L, Franzese C, Mazzola R, Franceschini D, Rigo M, D\u2019agostino G, Corradini S, Alongi F, Scorsetti M (2020) Recurrence pattern of stereotactic body radiotherapy in oligometastatic prostate cancer: a multi-institutional analysis. Strahlenther Onkol 196(3):213\u2013221. https:\/\/doi.org\/10.1007\/s00066-019-01523-9","journal-title":"Strahlenther Onkol"}],"container-title":["La radiologia medica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-022-01479-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11547-022-01479-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11547-022-01479-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T17:18:16Z","timestamp":1652375896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11547-022-01479-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,26]]},"references-count":52,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["1479"],"URL":"https:\/\/doi.org\/10.1007\/s11547-022-01479-4","relation":{},"ISSN":["1826-6983"],"issn-type":[{"value":"1826-6983","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,26]]},"assertion":[{"value":"10 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}